Vector Labs Ab02327-10.3 Anti-CTLA-4 [CP-675,206 (Tremelimumab, 11.2.1)], Human IgG1, Fc Silent™, kappa (200 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: CP-675,206 (Tremelimumab, 11.2.1)
Heavy Chain Modification: Fc Silent™
Synonyms: CD152; CTLA4; Cytotoxic T-lymphocyte protein; Cytotoxic T-lymphocyte-associated antigen 4
Amount: 200 μg
Application Codes Clone: FC, Block, ELISA
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG2 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody binds human and cynomolgus monkey CTLA4 and does not cross react with mouse, hamster, rat, or rabbit CTLA4.
Application Notes: Formerly known as ticilimumab, this anitbody is a fully human anti-huCTLA4 antagonist. It binds human and cycynomolgus monkey CTLA4 in flow cytometric analysis. It binds immobilized human and monkey CTLA4-Ig with average affinities of 0.28 and 0.98 nM, respectively. It is also reported that this antibody does not induce release of cytokines and also does not bind to human leukocyte Fc receptors. It blocks binding of human CTLA4-Ig to immobilized B7.1 and B7.2 with average IC50 values of 0.65 and 0.50 nM in competition binding studies. It was reported to enhance IL-2 and interferon-gamma production in human T cell blasts stimulated with B7-positive Raji cells and also enhanced IL-2 production in a concentration dependent manner in human and cynomolgus monkey whole blood (WB) and peripheral blood mononuclear cells (PBMC) stimulated with staphylococcal enterotoxin A (SEA) superantigen (Hansen et al, 2004). Phase I clinical trial with patients having advanced solid malignancies revealed that this antibody was safe and well tolerated and the related autoimmunity caused is reversible (Camacho et al., 2004). Phase 1 clinical trials in patients with advanced melanoma suggested that this antibody can be safely administered in a recommended dosage of 10 mg/kg every month and has antitumor activity in melanoma at monthly doses consistent with prolonged CTLA4 blockade (Ribas et al., 2005). It is also reported that therapy with this antibody reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (Reuben et al., 2005).

Product Class:	Purified
Clone ID:	CP-675,206 (Tremelimumab, 11.2.1)
Heavy Chain Modification:	Fc Silent™
Synonyms:	CD152; CTLA4; Cytotoxic T-lymphocyte protein; Cytotoxic T-lymphocyte-associated antigen 4
Amount:	200 μg
Application Codes Clone:	FC, Block, ELISA
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted human antibody was made using the variable domain sequences of the original Human IgG2 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody binds human and cynomolgus monkey CTLA4 and does not cross react with mouse, hamster, rat, or rabbit CTLA4.
Application Notes:	Formerly known as ticilimumab, this anitbody is a fully human anti-huCTLA4 antagonist. It binds human and cycynomolgus monkey CTLA4 in flow cytometric analysis. It binds immobilized human and monkey CTLA4-Ig with average affinities of 0.28 and 0.98 nM, respectively. It is also reported that this antibody does not induce release of cytokines and also does not bind to human leukocyte Fc receptors. It blocks binding of human CTLA4-Ig to immobilized B7.1 and B7.2 with average IC50 values of 0.65 and 0.50 nM in competition binding studies. It was reported to enhance IL-2 and interferon-gamma production in human T cell blasts stimulated with B7-positive Raji cells and also enhanced IL-2 production in a concentration dependent manner in human and cynomolgus monkey whole blood (WB) and peripheral blood mononuclear cells (PBMC) stimulated with staphylococcal enterotoxin A (SEA) superantigen (Hansen et al, 2004). Phase I clinical trial with patients having advanced solid malignancies revealed that this antibody was safe and well tolerated and the related autoimmunity caused is reversible (Camacho et al., 2004). Phase 1 clinical trials in patients with advanced melanoma suggested that this antibody can be safely administered in a recommended dosage of 10 mg/kg every month and has antitumor activity in melanoma at monthly doses consistent with prolonged CTLA4 blockade (Ribas et al., 2005). It is also reported that therapy with this antibody reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (Reuben et al., 2005).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews